Smith & Nephew SNATS, Inc. (SNN): Price and Financial Metrics
SNN Stock Summary
- With a market capitalization of $17,458,788,883, Smith & Nephew Plc has a greater market value than 86.95% of US stocks.
- With a year-over-year growth in debt of 80.26%, Smith & Nephew Plc's debt growth rate surpasses 87.96% of about US stocks.
- The volatility of Smith & Nephew Plc's share price is greater than that of merely 4.04% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Smith & Nephew Plc are XYL, STE, ESI, MFGP, and DCI.
- Visit SNN's SEC page to see the company's official filings. To visit the company's web site, go to www.smith-nephew.com.
SNN Stock Price Chart Interactive Chart >
SNN Price/Volume Stats
| Current price | $39.65 | 52-week high | $46.10 |
| Prev. close | $39.46 | 52-week low | $34.29 |
| Day low | $39.31 | Volume | 489,197 |
| Day high | $39.75 | Avg. volume | 451,376 |
| 50-day MA | $39.46 | Dividend yield | 2.28% |
| 200-day MA | $40.27 | Market Cap | 17.42B |
Smith & Nephew SNATS, Inc. (SNN) Company Bio
Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. The Company operates in two segments: Advanced Surgical Devices and Advanced Wound Management. The company was founded in 1856 and is based in London, the United Kingdom.
SNN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $39.65 | $2.58 | -94% |
We started the process of determining a valid price forecast for Smith & Nephew Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Smith & Nephew Plc ranked in the 11th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 93.67%. In terms of the factors that were most noteworthy in this DCF analysis for SNN, they are:
- The company's compound free cash flow growth rate over the past 5.07 years comes in at -0.09%; that's greater than just 14.88% of US stocks we're applying DCF forecasting to.
- As a business, SNN is generating more cash flow than 69.29% of positive cash flow stocks in the Healthcare.
- Smith & Nephew Plc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -94% |
| 1% | -94% |
| 2% | -94% |
| 3% | -94% |
| 4% | -93% |
| 5% | -93% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as SNN, try NVST, ANIK, XOMA, ANGO, and BKD.
Latest SNN News From Around the Web
Below are the latest news stories about Smith & Nephew Plc that investors may wish to consider to help them evaluate SNN as an investment opportunity.
Are Smith & Nephew plc's (LON:SN.) Mixed Financials Driving The Negative Sentiment?Smith & Nephew (LON:SN.) has had a rough three months with its share price down 14%. We, however decided to study the... |
The Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and MedtronicThe Zacks Analyst Blog Highlights: Smith & Nephew, Intuitive Surgical, Stryker Corp, Accuray and Medtronic |
Smith+Nephew adds Movendo Technology's patient rehabilitation solution to Real Intelligence digital ecosystemSmith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces a marketing collaboration with Movendo Technology (Genoa, Italy) that will add personalised robotic patient rehabilitation capability to Smith+Nephew's Real Intelligence enabling technology solutions, creating a fully digitised patient pathway from the pre-op stage to post-rehab phase. The collaboration has launched in Europe and will expand to other regions in the near future. |
Bone Implant Market Undertake Strapping Growth By 2027 With B. Braun Melsungen AG, Biotronic, Conmed Corporation, Globus Medical, Medtronic Plc, Stryker Corporation, Zimmer Biomet Holdings, DePuySynthes, Wright Medical Group N.V, Smith & Nephew plcBone Implant research report provides deep insights into the Global Bone Implant market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the |
Smith+Nephew's ALLEVYN™ LIFE Foam Dressings halved change frequency, significantly reduced cost and improved treatment satisfaction in real-world studySmith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce the results of a real-world study from Spain that showed how a switch to ALLEVYN LIFE Foam Dressings helped to significantly reduce dressing change frequency and weekly dressing costs, while improving treatment satisfaction for clinicians and patients in a community setting.*1 |
SNN Price Returns
| 1-mo | 5.87% |
| 3-mo | -12.54% |
| 6-mo | 4.27% |
| 1-year | 2.83% |
| 3-year | 8.91% |
| 5-year | 30.10% |
| YTD | -4.85% |
| 2020 | -10.45% |
| 2019 | 30.78% |
| 2018 | 8.84% |
| 2017 | 18.54% |
| 2016 | -13.98% |
SNN Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching SNN
Here are a few links from around the web to help you further your research on Smith & Nephew Plc's stock as an investment opportunity:Smith & Nephew Plc (SNN) Stock Price | Nasdaq
Smith & Nephew Plc (SNN) Stock Quote, History and News - Yahoo Finance
Smith & Nephew Plc (SNN) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...